APEH

Across TCGA pan-cancer cohorts, APEH mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated APEH data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher APEH mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APEH expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where APEH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.954	0.646	<.001	38	view →
PDAC	DFS	Quartile	All	0.581	0.307	.001	31	view →
LUAD	DFS	Median	III,IV	0.315	0.948	.008	8	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
HNSC	OS	Median	All	1.000	0.449	.023	6	view →
LSCC	DFS	Median	III,IV	0.489	0.820	.028	5	view →
OV	DFS	Median	All	0.886	0.583	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

APEH–CCRCC (DFS)

Open the CCRCC breakdown →